Please assess the completion status of the following clinical trial:

Trial Title: RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Patient \> 18 years old~* Histologically confirmed diagnosis of melanoma~* Previously treated or previously untreated metastatic melanoma by AJCC staging criteria~* Presence of an index lesion \> 1 cm amenable to hypofractionated radiotherapy and at least one other additional lesion that can be followed for response using RECIST criteria~* ECOG Performance status 0 or 1~* Signed informed consent document~* Ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold position for treatment)~Exclusion Criteria~* Prior systemic therapy within 14 days of study enrollment. Patients must be adequately recovered from prior systemic therapy side effects as deemed by the PI.~* Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)~* Presence or history of central nervous system metastasis (including brain)~* Long-term use of systemic corticosteroids~* Prior RT that precludes the delivery of hypofractionated radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab and Radiotherapy (8 Gy x 2) (Type: EXPERIMENTAL): None
- Ipilimumab and Radiotherapy (8 Gy x 3) (Type: EXPERIMENTAL): None
- Ipilimumab and Radiotherapy (6 Gy x 2) (Type: EXPERIMENTAL): None
- Ipilimumab and Radiotherapy (6 Gy x 3) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).